參考文獻(xiàn)/References:
[1] MCCORMICK J R,SAMA A J,SCHILLER N C,et al.Cervical spondylotic myelopathy:a guide to diagnosis and management[J].J Am Board Fam Med,2020,33(2):303-313.
[2] DONNALLY C J 3rd,PATEL P D,CANSECO J A,et al.Current management of cervical spondylotic myelopathy[J].Clin Spine Surg,2022,35(1):E68-E76.
[3] 段寒,譚洪宇,張楊,等.頸椎曲度與脊髓型頸椎病的關(guān)系研究[J].中醫(yī)正骨,2022,34(1):8-12.
[4] KADAÑKA Z,BEDNARÍK J,NOVOTNY O,et al.Cervical spondylotic myelopathy:conservative versus surgical treatment after 10 years[J].Eur Spine J,2011,20(9):1533-1538.
[5] 陳印磊,夏建龍,蔡平.中醫(yī)對脊髓型頸椎病的認(rèn)識及治療進(jìn)展[J].中醫(yī)藥臨床雜志,2018,30(10):1957-1961.
[6] 禚漢杰,周英杰,王少純,等.從“督”論治脊髓型頸椎病[J].中國中醫(yī)骨傷科雜志,2018,26(2):57-60.
[7] 睦順姬,葉秀蘭,姚敏,等.中醫(yī)藥治療脊髓型頸椎病的機(jī)理研究概況[J].世界中醫(yī)藥,2017,12(1):222-224.
[8] 莫文,王擁軍,吳弢,等.施杞運用中醫(yī)藥治療頸椎病的經(jīng)驗[J].上海中醫(yī)藥雜志,2017,51(11):1-5.
[9] 陸洋,謝林.基于“腎主骨生髓”辨治脊髓型頸椎病的經(jīng)驗[J].上海中醫(yī)藥雜志,2019,53(12):30-32.
[10] 中國中西醫(yī)結(jié)合學(xué)會骨傷科分會,莫文,袁文.脊髓型頸椎病中西醫(yī)結(jié)合診療專家共識[J].中國骨傷,2022,35(8):790-798.
[11] 文天林,孫天勝.脊髓型頸椎病的病理演變和治療研究進(jìn)展[J].人民軍醫(yī),2017,60(1):75-76.
[12] MORISHITA Y,FALAKASSA J,NAITO M,et al.The kinematic relationships of the upper cervical spine[J].Spine(Phila Pa 1976),2009,34(24):2642-2645.
[13] DOPPMAN J L.The mechanism of ischemia in anteropos-terior compression of the spinal cord[J].Invest Radiol,1975,10(6):543-551.
[14] 陳鋒,施杞,韋貴康,等.脊髓型頸椎病脊髓微循環(huán)改變及中藥效應(yīng)觀察[J].中醫(yī)正骨,2004,16(10):3-4.
[15] 唐彬,朱立國,陳忻,等.益腎養(yǎng)髓方對脊髓型頸椎病大鼠受損脊髓微血管再生的影響[J].中國中醫(yī)藥信息雜志,2022,29(5):51-55.
[16] 陳鋒,黃有榮,崔偉,等.活血方對脊髓型頸椎病脊髓微循環(huán)的影響[J].廣西中醫(yī)藥,2014,37(3):75-77.
[17] 王羽豐.補(bǔ)腎活血方治療脊髓型頸椎病療效及與內(nèi)皮素關(guān)系的研究[D].廣州:廣州中醫(yī)藥大學(xué),2002.
[18] 曲安龍.益腎通絡(luò)湯對脊髓型頸椎病患者ET表達(dá)水平的影響及療效觀察[J].陜西中醫(yī),2017,38(5):601-602.
[19] 歐傳雙.補(bǔ)氣通絡(luò)法對脊髓型頸椎病術(shù)后Aβ蛋白、血漿內(nèi)皮素、一氧化氮表達(dá)的影響[D].廣州:廣州中醫(yī)藥大學(xué),2017.
[20] 李志強(qiáng),袁尚榮,陳澤斌.三七總皂甙對大鼠脊髓損傷后一氧化氮合酶表達(dá)的影響[J].中國脊柱脊髓雜志,2001,11(4):197-198.
[21] 周思啟.脊髓型頸椎病患者頸椎間盤IL-1β、IL-6、IL-8和TNF-α水平與JOA評分的相關(guān)性研究[D].合肥:安徽醫(yī)科大學(xué),2007.
[22] 王洪流,董又坤,廖志剛,等.花椒毒酚對大鼠脊髓型頸椎病的治療作用及機(jī)制[J].新鄉(xiāng)醫(yī)學(xué)院學(xué)報,2021,38(10):917-923.
[23] 周龍云.參芪麝蓉丸抑制線粒體過度分裂干預(yù)脊髓型頸椎病神經(jīng)炎癥反應(yīng)的機(jī)制研究[D].上海:上海中醫(yī)藥大學(xué),2020.
[24] 楊家祥,楊環(huán)瑋,董軍格,等.丹紅提取物對脊髓型頸椎病的治療機(jī)制初探[J].中國醫(yī)科大學(xué)學(xué)報,2017,46(8):710-712.
[25] 丁海霞,樊成虎,王玉泉,等.黃芪總苷對脊髓型頸椎病大鼠模型椎間盤細(xì)胞因子IL-6、TNF-α的影響[J].西部中醫(yī)藥,2017,30(7):20-25.
[26] 唐占英,王擁軍,胡志俊,等.益氣化瘀補(bǔ)腎方對壓迫和減壓后大鼠背根節(jié)神經(jīng)元PLA2、PGE2表達(dá)影響[J].四川中醫(yī),2012,30(9):36-39.
[27] 楊宇.益氣活血方治療大鼠脊髓型頸椎病的實驗研究[D].南京:南京中醫(yī)藥大學(xué),2016.
[28] ASHOK A,ANDRABI S S,MANSOOR S,et al.Antioxidant therapy in oxidative stress-induced neurodegenerative diseases:role of nanoparticle-based drug delivery systems in clinical translation[J].Antioxidants(Basel),2022,11(2):408.
[29] KANG Y,LI Q,ZHU R,et al.Identification of ferroptotic genes in spinal cord injury at different time points:bioinformatics and experimental validation[J].Mol Neurobiol,2022,59(9):5766-5784.
[30] ANJUM A,YAZID M D,FAUZI DAUD M,et al.Spinal cord injury:pathophysiology,multimolecular interactions,and underlying recovery mechanisms[J].Int J Mol Sci,2020,21(20):7533.
[31] WILSON J X,GELB A W.Free radicals,antioxidants,and neurologic injury:possible relationship to cerebral protection by anesthetics[J].J Neurosurg Anesthesiol,2002,14(1):66-79.
[32] CHEN Y,ZHANG J,LIN Y,et al.Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS[J].EMBO Rep,2011,12(6):534-541.
[33] 田子睿.參芪麝蓉丸治療脊髓型頸椎病的機(jī)制研究[D].上海:上海中醫(yī)藥大學(xué),2019.
[34] KLINEBERG E.Cervical spondylotic myelopathy:a review of the evidence[J].Orthop Clin North Am,2010,41(2):193-202.
[35] TRACY J A,BARTLESON J D.Cervical spondylotic mye-lopathy[J].Neurologist,2010,16(3):176-187.
[36] 韋貴康,陳鋒,韋堅,等.中藥“脊髓康”內(nèi)服治療脊髓型頸椎病32例臨床觀察與實驗研究[J].廣西中醫(yī)學(xué)院學(xué)報,2001,4(4):86-88.
[37] CHEN D F,SCHNEIDER G E,MARTINOU J C,et al.Bcl-2 promotes regeneration of severed axons in mammalian CNS[J].Nature,1997,385(6615):434-439.
[38] 徐遠(yuǎn)坤.“健身丹”對脊髓型頸椎病神經(jīng)細(xì)胞凋亡相關(guān)基因表達(dá)影響的研究[D].貴陽:貴陽中醫(yī)學(xué)院,2007.
[39] GAUDET A D,FONKEN L K.Glial cells shape pathology and repair after spinal cord injury[J].Neurotherapeutics,2018,15(3):554-577.
[40] 秦曉寬,銀河,楊博文,等.益腎養(yǎng)髓方對脊髓型頸椎病大鼠脊髓中星形膠質(zhì)細(xì)胞過度增殖的影響[J].中藥新藥與臨床藥理,2022,33(2):173-179.
[41] HERRMANN J E,IMURA T,SONG B,et al.STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury[J].Neurosci,2008,28(28):7231-7243.
[42] WANG Y,LAI X,WU D,et al.Umbilical mesenchymal stem cell-derived exosomes facilitate spinal cord functional recovery through the miR-199a-3p/145-5p-mediated NGF/TrkA signaling pathway in rats[J].Stem Cell Res Ther,2021,12(1):117.
[43] XU Z X,ZHANG L Q,ZHOU Y N,et al.Histological and functional outcomes in a rat model of hemisected spinal cord with sustained VEGF/NT-3 release from tissue-engineered grafts[J].Artif Cells Nanomed Biotechnol,2020,48(1):362-376.
中醫(yī)正骨2023年12月第35卷第12期 J Trad Chin Orthop Trauma,2023,Vol.35,No.12(總921)
(總922)中醫(yī)正骨2023年12月第35卷第12期 J Trad Chin Orthop Trauma,2023,Vol.35,No.12
[44] 唐彬,銀河,楊博文,等.益腎養(yǎng)髓方對脊髓型頸椎病大鼠脊髓中神經(jīng)營養(yǎng)因子表達(dá)的影響及其神經(jīng)修復(fù)作用研究[J].中國全科醫(yī)學(xué),2021,24(35):4447-4456.
[45] 謝興文,施杞,王擁軍.益氣化瘀補(bǔ)腎方對大鼠慢性脊髓損傷后影響的實驗研究[J].上海中醫(yī)藥雜志,2009,43(8):61-63.
[46] LIANG H Z,LUO R J,LI G C,et al.The proteolysis of ECM in intervertebral disc degeneration[J].Int J Mol Sci,2022,23(3):1715.
[47] GREENE J,WANG M,LIU Y E,et a1.Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4[J].J Biol Chem,1996,271(48):30375-30380.
[48] 施杞,王擁軍,李晨光,等.益氣化瘀補(bǔ)腎方及拆方影響椎間盤細(xì)胞外基質(zhì)膠原和代謝酶mRNA表達(dá)的研究[J].中國中西醫(yī)結(jié)合雜志,2007,27(2):142-146.
[49] 李具寶,趙紅云,趙永見,等.益氣化瘀補(bǔ)腎方對退變椎間盤細(xì)胞蛋白聚糖和X型膠原mRNA表達(dá)的影響[J].中西醫(yī)結(jié)合學(xué)報,2011,9(10):1138-1144.
[50] 趙飛,王其友.淫羊藿苷對大鼠腰椎間盤退變影響的實驗研究[J].遼寧中醫(yī)藥大學(xué)學(xué)報,2015,17(10):36-38.
[51] 宋永嘉.參芪麝蓉丸調(diào)控BDNF/TrkB信號通路對大鼠頸髓雙節(jié)段雙側(cè)慢性壓迫模型神經(jīng)功能恢復(fù)的研究[D].上海:上海中醫(yī)藥大學(xué),2020.
[52] CHENG X,YU Z,XU J,et al.Pathophysiological changes and the role of Notch-1 activation after decompression in a compressive spinal cord injury rat model[J].Front Neurosci,2021,15:579431.
[53] 勞澤輝,凌國偉,華國花.circRNAs調(diào)控NF-κB信號通路在脊髓型頸椎病中的作用及機(jī)制研究[J].中國醫(yī)學(xué)工程,2022,30(12):24-28.
[54] LIU H,ZHANG J,XU X,et al.SARM1 promotes neuroinflammation and inhibits neural regeneration after spinal cord injury through NF-κB signaling[J].Theranostics,2021,11(9):4187-4206.
[55] XU S,WANG J,JIANG J,et al.TLR4 promotes microglial pyroptosis via lncRNA-F630028O10Rik by activating PI3K/AKT pathway after spinal cord injury[J].Cell Death Dis,2020,11(8):693.
[56] WANG X,FU Y,BOTCHWAY B O A,et al.Quercetin can improve spinal cord injury by regulating the mTOR signaling pathway[J].Front Neurol,2022,13:905640.
[57] WANG Y F,ZU J N,LI J,et al.Curcumin promotes the spinal cord repair via inhibition of glial scar formation and inflammation[J].Neurosci Lett,2014,560:51-56.
[58] MENG H Y,SHAO D C,LI H,et al.Resveratrol improves neurological outcome and neuroinflammation following spinal cord injury through enhancing autophagy involving the AMPK/mTOR pathway[J].Mol Med Rep,2018,18(2):2237-2244.
[59] 敬聰,王志剛,王君,等.脊髓損傷相關(guān)信號通路在脊髓損傷修復(fù)過程中的研究進(jìn)展[J].中國醫(yī)藥導(dǎo)報,2021,18(16):52-55.